A systematic review of epinephrine stability and sterility with storage in a syringe

Allergy, Asthma & Clinical Immunology
• 
  
• 
  
• Research
• Open Access

• Hannah G. Parish,
• Jacquelyn R. Morton and
• Julie C. BrownEmail author

Allergy, Asthma & Clinical Immunology201915:7

Abstract

Background

Epinephrine is a lifesaving medication in the treatment of anaphylaxis. Epinephrine auto-injectors are the preferred method of epinephrine administration, but are not universally available or affordable.

Immediate hypersensitivity to polyethylene glycols in unrelated products: when standardization in the nomenclature of the components of drugs, cosmetics, and food becomes necessary

• Case report
• Open Access

Allergy, Asthma & Clinical Immunology

• Vicente Jover CerdáEmail author,
• Ramón Rodríguez Pacheco,
• Joan Doménech Witek,
• Francisco Manuel Marco de la Calle and
• María Luz de la Sen Fernández

Allergy, Asthma & Clinical Immunology201915:9

Abstract

Background

Polyethylene glycols (PEGs) and their derivatives are non-ionic polymers of ethylene oxide commercially available with numerous synonyms, such as macrogol, oxyethylene polymer, and laureth-9. Although these polymers are usually safe, mild to life-threatening immediate-type hypersensitivity reactions have been reported.

Asthma and atopy prevalence are not reduced among former tuberculosis patients compared with controls in Lima, Peru

BMC Pulmonary Medicine 
• Research article
• Open Access
• Open Peer Review
• 
  

• Anthony L. ByrneEmail authorView ORCID ID profile,
• Ben J. Marais,
• Carole D. Mitnick,
• Frances L. Garden,
• Leonid Lecca,
• Carmen Contreras,
• Yaninna Yauri,
• Fanny Garcia and
• Guy B. Marks

BMC Pulmonary Medicine201919:40

https://doi.org/10.1186/s12890-019-0804-z

Abstract

Background

Although there are theoretical reasons for believing that asthma and atopy may be negatively correlated with tuberculosis, epidemiological studies have had conflicting findings.

POLLAR: Impact of air POLLution on Asthma and Rhinitis; a European Institute of Innovation and Technology Health (EIT Health) project

Clinical and Translational Allergy


• Review
• Open Access

• Jean BousquetEmail authorView ORCID ID profile,
 
• Josep M. Anto,
 
• Isabella Annesi-Maesano,
 
• Toni Dedeu,
 
• Eve Dupas,
 
• Jean-Louis Pépin,
 
• Landry Stephane Zeng Eyindanga,
 
• Sylvie Arnavielhe,
 
• Julia Ayache,
 
• Xavier Basagana,
 
• Samuel Benveniste,
 
• Nuria Calves Venturos,
 
• Hing Kin Chan,
 
• Mehdi Cheraitia,
 
• Yves Dauvilliers,
 
• Judith Garcia-Aymerich,
 
• Ingrid Jullian-Desayes,
 
• Chitra Dinesh,
 
• Daniel Laune,
 
• Jade Lu Dac,
 
• Ismael Nujurally,
 
• Giovanni Pau,
 
• Robert Picard,
 
• Xavier Rodo,
 
• Renaud Tamisier,
 
• Michael Bewick,
 
• Nils E. Billo,
 
• Wienczyslawa Czarlewski,
 
• Joao Fonseca,
 
• Ludger Klimek,
 
• Oliver Pfaar and
 
• Jean-Marc Bourez

Clinical and Translational Allergy20188:36

https://doi.org/10.1186/s13601-018-0221-z

Abstract

Allergic rhinitis (AR) is impacted by allergens and air pollution but interactions between air pollution, sleep and allergic diseases are insufficiently understood. POLLAR (Impact of air POLLution on sleep, Asthma and Rhinitis) is a project of the European Institute of Innovation and Technology (EIT Health).

Obstructive sleep apnea and comorbidities: a dangerous liaison

Multidisciplinary Respiratory Medicine REVIEW

Maria R. Bonsignore, Pierpaolo Baiamonte, Emilia Mazzuca, Alessandra Castrogiovanni and Oreste Marrone

Multidisciplinary Respiratory Medicine 2019, 14:8  Abstract Obstructive sleep apnea (OSA) is a highly prevalent disease, and is traditionally associated with increased cardiovascular risk. The role of comorbidities in OSA patients has emerged recently, and new conditions significantly associated with OSA are increasingly reported.

DP2 antagonism reduces airway smooth muscle mass in asthma by decreasing eosinophilia and myofibroblast recruitment

Science Translational Medicine

Vol 11, Issue 479 13 February 2019

Ruth Saunders1,*, 

Himanshu Kaul1,2,*,†,‡, 

Rachid Berair1,*, 

Sherif Gonem1, 

Amisha Singapuri1, 

Amanda J. Sutcliffe1, 

Latifa Chachi1, 

Michael S. Biddle1, 

Davinder Kaur1, 

Michelle Bourne1, 

Ian D. Pavord3, 

Andrew J. Wardlaw1, 

Salman H. Siddiqui1, 

Richard A. Kay4,§, 

Bindi S. Brook5, 

Rod H. Smallwood2,|| and 

Christopher E. Brightling1,†,||

 See all authors and affiliations

Science Translational Medicine  13 Feb 2019:
Vol. 11, Issue 479, eaao6451
DOI: 10.1126/scitranslmed.aao6451

• Article
• Figures & Data
• Info & Metrics
• eLetters
•  PDF

Smoothing out muscle in asthma

Asthma is often treated with drugs that reduce airway inflammation. Saunders et al. now show that fevipiprant, a prostaglandin D2 type 2 receptor antagonist, reduced smooth muscle mass in bronchial biopsies from asthma patients. Computational simulations of an asthmatic airway predicted that this decrease in airway smooth muscle mass was due to both amelioration of inflammation observed in a prior clinical trial together with direct effects on migration of myofibroblasts.

Age distribution and seasonality in acute eosinophilic pneumonia: analysis using a national inpatient database

• Research article
• Open Access
• Open Peer Review
• 
  

BMC Pulmonary Medicine

• Koshi OtaEmail authorView ORCID ID profile,
• Yusuke Sasabuchi,
• Hiroki Matsui,
• Taisuke Jo,
• Kiyohide Fushimi and
• Hideo Yasunaga

BMC Pulmonary Medicine201919:38

Abstract

Background

Acute eosinophilic pneumonia (AEP) is a rare inflammatory lung disease. Previous studies have shown that most patients with AEP are aged 20 to 40 years, whereas several case studies have included older patients with AEP. These studies also suggested that AEP is more prevalent in summer, but they were limited due to their small sample sizes. We therefore investigated the age distribution and seasonality among patients with AEP using a national inpatient database.